TCT-338 Comparison of Re-Do transcatheter aortic valve replacement with valve-in-valve for failed surgical aortic bioprostheses: a multicenter analysis of clinical and long-term outcome

Matthias Raschpichler,Felix Woitek,Tarun Chakravarty,Chetana Singh,Mohammad Kashif,Chinar Patel,Jasminka Stegic,Stephan Haussig,Philipp Kiefer,Norman Mangner,David Holzhey,Axel Linke,Holger Thiele,Michael Borger,Raj Makkar

doi:10.1016/j.jacc.2018.08.1484

TCT-338 Comparison of Re-Do transcatheter aortic valve replacement with valve-in-valve for failed surgical aortic bioprostheses: a multicenter analysis of clinical and long-term outcome

Matthias Raschpichler, Felix Woitek + Show 13 more

Open Access

https://doi.org/10.1016/j.jacc.2018.08.1484

Copy DOI

Journal: Journal of the American College of Cardiology	Publication Date: Sep 1, 2018
License type: elsevier-specific: oa user license

Affiliation: Cedars-Sinai Medical Center, TU Dresden, Leipzig Heart Institute, University Hospital Carl Gustav Carus, University Hospital Leipzig

#Re-Do Transcatheter Aortic Valve Replacement #Surgical Aortic Valve Replacement + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Valve-in-Valve (ViV) for failed surgical aortic valve replacement (SAVR) is an effective treatment for patients that are not able to undergo re-operation. Limited data exist for transcatheter aortic valve replacement (TAVR) as a redo for patients that have undergone TAVR procedures. Baseline

Full Text